Cargando…

Nutrigenetics-based intervention approach for adults with non-alcoholic fatty liver disease (NAFLD): study protocol for a randomised controlled feasibility trial

INTRODUCTION: Lifestyle interventions targeting weight loss and improved dietary patterns are the recommended treatment for non-alcoholic fatty liver disease (NAFLD). However, the effectiveness of current established diet therapies is suboptimal. The patatin‐like phospholipase domain containing 3 (P...

Descripción completa

Detalles Bibliográficos
Autores principales:	Haigh, Laura, McPherson, Stuart, Mathers, John C, Anstee, Quentin M
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2021
Materias:	Gastroenterology and Hepatology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8039279/ http://dx.doi.org/10.1136/bmjopen-2020-045922

Ejemplares similares

Does moderate alcohol consumption accelerate the progression of liver disease in NAFLD? A systematic review and narrative synthesis
por: Jarvis, Helen, et al.
Publicado: (2022)

Cohort profile: the Trivandrum non-alcoholic fatty liver disease (NAFLD) cohort
por: Chalmers, Jane, et al.
Publicado: (2019)

Factors associated with engagement and adherence to a low-energy diet to promote 10% weight loss in patients with clinically significant non-alcoholic fatty liver disease
por: Scragg, Jadine, et al.
Publicado: (2021)

The association between non-alcoholic fatty liver disease (NAFLD) and advanced fibrosis with blood selenium level based on the NHANES 2017-2018
por: Liu, Jie, et al.
Publicado: (2022)

Plasma DNA methylation: a potential biomarker for stratification of liver fibrosis in non-alcoholic fatty liver disease
por: Hardy, Timothy, et al.
Publicado: (2017)

Efficacy and safety of guanabenz acetate treatment for non-alcoholic fatty liver disease: a study protocol for a randomised investigator-initiated phase IIa study
por: Iwaki, Michihiro, et al.
Publicado: (2022)

Efficacy and safety of an orally administered DGAT2 inhibitor alone or coadministered with a liver-targeted ACC inhibitor in adults with non-alcoholic steatohepatitis (NASH): rationale and design of the phase II, dose-ranging, dose-finding, randomised, placebo-controlled MIRNA (Metabolic Interventions to Resolve NASH with fibrosis) study
por: Amin, Neeta B, et al.
Publicado: (2022)

Does knowledge of liver fibrosis affect high-risk drinking behaviour (KLIFAD)? protocol for a feasibility randomised controlled trial
por: Subhani, Mohsan, et al.
Publicado: (2021)

Protocol for faecal microbiota transplantation in ulcerative colitis (FMTUC): a randomised feasibility study
por: Jitsumura, Maki, et al.
Publicado: (2018)

Economic evaluation of a community-based diagnostic pathway to stratify adults for non-alcoholic fatty liver disease: a Markov model informed by a feasibility study
por: Tanajewski, Lukasz, et al.
Publicado: (2017)

Comparison of laboratory indices of non-alcoholic fatty liver disease for the detection of incipient kidney dysfunction
por: Choi, Jong Wook, et al.
Publicado: (2019)

Effects of sleep quality on non-alcoholic fatty liver disease: a cross-sectional survey
por: Takahashi, Atsushi, et al.
Publicado: (2020)

Clinical outcome of non-alcoholic fatty liver disease: an 11-year follow-up study
por: Tang, Xiaoping, et al.
Publicado: (2022)

Association between serum and dietary antioxidant micronutrients and advanced liver fibrosis in non-alcoholic fatty liver disease: an observational study
por: Coelho, Juliana Moraes, et al.
Publicado: (2020)

Mental Imagery to Reduce Alcohol-related harm in patients with alcohol dependence and alcohol-related liver damaGE: the MIRAGE pilot trial protocol
por: Dhanda, Ashwin D, et al.
Publicado: (2022)

Adiponectin–leptin ratio for the early detection of lean non-alcoholic fatty liver disease independent of insulin resistance
por: Lu, Chia-Wen, et al.
Publicado: (2023)

Home-based exercise therapy in patients awaiting liver transplantation: protocol for an observational feasibility trial
por: Williams, Felicity Rhian, et al.
Publicado: (2018)

High potency multistrain probiotic improves liver histology in non-alcoholic fatty liver disease (NAFLD): a randomised, double-blind, proof of concept study
por: Duseja, Ajay, et al.
Publicado: (2019)

Rationale and design of a randomised, double-blind, placebo-controlled, parallel-group, investigator-initiated phase 2a study to investigate the efficacy and safety of elobixibat in combination with cholestyramine for non-alcoholic fatty liver disease
por: Kessoku, Takaomi, et al.
Publicado: (2020)

Non-alcoholic steatofibrosis (NASF) can independently predict mortality in patients with non-alcoholic fatty liver disease (NAFLD)
por: Golabi, Pegah, et al.
Publicado: (2018)

Association of physical activity and fine motor performance in individuals with type 2 diabetes mellitus and/or non-alcoholic fatty liver disease
por: Weinstein, Ali A., et al.
Publicado: (2023)

Stages of psychological change among patients with non-alcoholic fatty liver disease in China: a national cross-sectional study
por: Huang, Rui, et al.
Publicado: (2023)

Relationship between triglyceride glucose index and the incidence of non-alcoholic fatty liver disease in the elderly: a retrospective cohort study in China
por: Huanan, Chen, et al.
Publicado: (2020)

Recurrent acute pancreatitis prevention by the elimination of alcohol and cigarette smoking (REAPPEAR): protocol of a randomised controlled trial and a cohort study
por: Ocskay, Klementina, et al.
Publicado: (2022)

Dose–response association between physical activity and non-alcoholic fatty liver disease: a case–control study in a Chinese population
por: Li, YangFan, et al.
Publicado: (2019)

Study protocol: a multicentre, open-label, parallel-group, phase 2, randomised controlled trial of autologous macrophage therapy for liver cirrhosis (MATCH)
por: Brennan, Paul Noel, et al.
Publicado: (2021)

Liraglutide efficacy and action in non-alcoholic steatohepatitis (LEAN): study protocol for a phase II multicentre, double-blinded, randomised, controlled trial
por: Armstrong, Matthew J, et al.
Publicado: (2013)

PROFIT, a PROspective, randomised placebo controlled feasibility trial of Faecal mIcrobiota Transplantation in cirrhosis: study protocol for a single-blinded trial
por: Woodhouse, Charlotte Alexandra, et al.
Publicado: (2019)

ATTIRE: Albumin To prevenT Infection in chronic liveR failurE: study protocol for an interventional randomised controlled trial
por: China, Louise, et al.
Publicado: (2018)

Atorvastatin for prevention of disease progression and hospitalisation in liver cirrhosis: protocol for a randomised, double-blind, placebo-controlled trial
por: Kimer, Nina, et al.
Publicado: (2020)

ATTIRE: Albumin To prevenT Infection in chronic liveR failurE: study protocol for a single-arm feasibility trial
por: China, Louise, et al.
Publicado: (2016)

Gender differences in the association of non-alcoholic fatty liver disease and metabolic syndrome with erosive oesophagitis: a cross-sectional study in a Taiwanese population
por: Hung, Wei-Chieh, et al.
Publicado: (2016)

In silico and in vivo demonstration of the regulatory mechanism of Qi-Ge decoction in treating NAFLD
por: Peng, Chong, et al.
Publicado: (2023)

Prevalence of and risk factors for non-alcoholic fatty liver disease (NAFLD) and fibrosis among young adults in Egypt
por: Tomah, Shaheen, et al.
Publicado: (2021)

Relevance of vitamin D on NAFLD and liver fibrosis detected by vibration controlled transient elastography in US adults: a cross-sectional analysis of NHANES 2017–2018
por: Ji, Yuan, et al.
Publicado: (2023)

Identification of patients with type 2 diabetes with non-alcoholic fatty liver disease who are at increased risk of progressing to advanced fibrosis: a cross-sectional study
por: Mettananda, Chamila, et al.
Publicado: (2023)

Protocol for a randomised, placebo-controlled pilot study for assessing feasibility and efficacy of faecal microbiota transplantation in a paediatric ulcerative colitis population: PediFETCh trial
por: Pai, Nikhil, et al.
Publicado: (2017)

Stratification Of LIver Disease (SOLID): protocol for a prospective observational cohort study to determine the optimum biomarker strategies for the detection of advanced liver disease at the primary–secondary care interface
por: McPherson, Stuart, et al.
Publicado: (2023)

Decision analytic model of the diagnostic pathways for patients with suspected non-alcoholic fatty liver disease using non-invasive transient elastography and multiparametric magnetic resonance imaging
por: Blake, Laurence, et al.
Publicado: (2016)

Effect of bariatric surgery on NAFLD/NASH: a single-centre observational prospective cohort study
por: Theel, Willy B, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_489g2e4hg7vi56t07jqlh75jno